Teriparatide: Side Effects
Known side effects, contraindications, and interactions
📌TL;DR
- •4 known side effects documented
- •4 mild, 0 moderate, 0 severe
- •4 contraindications listed
Compare side effects across multiple peptides →
Side Effects Severity Chart
Transient elevation of serum calcium above ULN reported in approximately 11% of patients. Typically peaks 4-6 hours post-injection and resolves within 16 hours. Usually asymptomatic; rarely requires dose modification.
Reported in approximately 9% of patients. May occur within minutes to hours of injection due to vasodilatory effects. Patients should sit or lie down if symptoms occur.
Reported in approximately 3% of patients. Mechanism unclear but may relate to calcium/phosphate flux effects on neuromuscular function.
Reported in approximately 9% of patients. Usually mild and does not require treatment discontinuation.
⛔Contraindications
- •Patients at increased risk for osteosarcoma (Paget disease, unexplained alkaline phosphatase elevation, open epiphyses, prior skeletal radiation)
- •Pre-existing hypercalcemia
- •Pregnancy (Category C; may cause fetal harm)
- •Known hypersensitivity to teriparatide or excipients
⚠️Drug Interactions
- •Digoxin: Hypercalcemia from teriparatide may predispose to digitalis toxicity. Monitor calcium and digoxin levels during concomitant use.
- •Thiazide diuretics: May potentiate hypercalcemia by reducing renal calcium excretion. Monitor serum calcium.
- •Hydrochlorothiazide: Specific interaction noted in labeling. Teriparatide can increase urinary calcium excretion, partially offset by thiazide effects, but net hypercalcemia risk remains.
Community-Reported Side Effects
See which side effects community members report most frequently.
Based on 80+ community reports
View community protocolsSafety Overview#
Teriparatide has the most extensive safety database of any osteoanabolic agent, with over 20 years of post-marketing surveillance since its November 2002 FDA approval. Safety data are derived from the Fracture Prevention Trial (n=1,637), the GIO trial (n=428), the VERO trial (n=1,360), and extensive post-marketing experience. The 2020 removal of the osteosarcoma boxed warning after 18 years of surveillance was a landmark regulatory reassurance.
Hypercalcemia#
Teriparatide transiently increases serum calcium through PTH1R-mediated effects on bone, kidney, and intestine. In clinical trials, hypercalcemia (serum calcium above ULN) was reported in approximately 11% of patients. This is higher than the 3.4% rate observed with abaloparatide, consistent with teriparatide's more prolonged R0 receptor signaling.
Key characteristics:
- Peak calcium elevation occurs 4-6 hours after injection
- Typically resolves to baseline by 16-24 hours post-dose
- Usually asymptomatic and does not require treatment modification
- Persistent or symptomatic hypercalcemia may warrant dose reduction in calcium supplementation, evaluation for other causes, or treatment discontinuation
Orthostatic Hypotension and Dizziness#
Dizziness was reported in approximately 9% of teriparatide patients. Orthostatic hypotension may occur within 4 hours of injection, likely mediated by PTH1R-induced vasodilation. In clinical trials, the incidence of orthostatic symptoms requiring intervention was low.
Patients should be counseled to:
- Administer injections where they can sit or lie down
- Rise slowly after sitting or lying down in the hours following injection
- Be aware that symptoms are most common during the first several doses
Leg Cramps#
Leg cramps are reported in approximately 3% of teriparatide patients. The mechanism is not fully established but may relate to transient fluctuations in calcium, phosphate, or magnesium levels affecting neuromuscular excitability.
Nausea and Headache#
Nausea occurs in approximately 9% and headache in approximately 8% of patients. Both are generally mild and do not require treatment discontinuation. Nausea may be reduced by administering injections at bedtime.
Other Reported Adverse Events#
| Adverse Event | Teriparatide 20 mcg | Placebo |
|---|---|---|
| Dizziness | 9% | 6% |
| Nausea | 9% | 5% |
| Headache | 8% | 5% |
| Leg cramps | 3% | 1% |
| Hypercalcemia | 11% | 2% |
| Injection site pain | 2% | 1% |
| Arthralgia | 10% | 8% |
Hyperuricemia#
Teriparatide has been associated with increases in serum uric acid levels. While the clinical significance is generally low, patients with a history of gout or hyperuricemia should be monitored. Gout exacerbations have been rarely reported.
Osteosarcoma: Resolved Safety Concern#
The osteosarcoma concern that led to the original boxed warning has been resolved:
- Rat finding: High-dose, near-lifetime teriparatide exposure in Fischer 344 rats caused osteosarcoma
- Species difference: Rats have continuous skeletal growth and lack osteonal remodeling; humans do not
- 18-year surveillance: No increased osteosarcoma in humans using teriparatide
- 2020 FDA action: Boxed warning removed; 2-year treatment limit removed
The labeling still recommends avoiding teriparatide in patients with increased baseline osteosarcoma risk (Paget disease, unexplained elevated ALP, open epiphyses, prior skeletal radiation).
Contraindications#
- Increased osteosarcoma risk: Paget disease, unexplained elevated ALP, open epiphyses, prior skeletal radiation
- Pre-existing hypercalcemia: May worsen calcium elevation
- Pregnancy: Category C; embryo-fetal effects in animal studies
- Known hypersensitivity: Allergic reaction to teriparatide or excipients
Drug Interactions#
Digoxin: Teriparatide-induced hypercalcemia may increase the risk of digitalis toxicity. Monitor serum calcium and digoxin levels.
Thiazide diuretics: May potentiate hypercalcemia. Monitor serum calcium more frequently.
CYP interactions: Teriparatide does not undergo CYP-mediated metabolism and does not inhibit or induce CYP enzymes.
Special Populations#
- Renal impairment: No dose adjustment for mild to moderate impairment. Use caution in severe CKD.
- Hepatic impairment: No dose adjustment required.
- Elderly (>65): No dose adjustment required. Clinical trials included elderly patients.
- Pediatric: Not indicated. Contraindicated in patients with open epiphyses.
Related Reading#
Unlock full side effects analysis
Free access to detailed safety profiles and interaction guidance for all peptides.
150+ peptide profiles · 30+ comparisons · 18 research tools
Frequently Asked Questions About Teriparatide
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.